At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Nivolumab for Cervical Adenocarcinoma and 5 related conditions. Active but no longer recruiting, targeting 26 participants across 332 sites.
Signals
Detailed Summary
This phase II trial studies the side effects and how well nivolumab works in treating patients with cervical cancer that has grown, come back, or spread to other places in the body. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.
Study Details
Timeline
Arms & Interventions
Patients receive nivolumab IV over approximately 60 minutes every 2 weeks for a maximum of 46 doses over 92 weeks in the absence of disease progression or unacceptable toxicity.
Interventions
Correlative studies
Given IV